Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | PCLX-001 |
Trade Name | |
Synonyms | PCLX 001|PCLX001 |
Drug Descriptions |
PCLX-001 inhibits the N-myristoyl-transferases NMT1 and NMT2, potentially resulting in inhibition of early B-cell receptor signaling and degradation of pERK, c-Myc, NFkappaB and CREB, which may lead to apoptosis and decreased tumor cell proliferation (Blood (2019) 134 (Supplement_1): 3362, Cancer Res 2020;80(16 Suppl):Abstract nr 5156). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C180576 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
PCLX-001 | PCLX-001 | 0 | 1 |